Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Serono identifies UK as personalised meds laggard

This article was originally published in Clinica

Executive Summary

Makers of personalised cancer medicines trying to sell their products in the UK may be fighting a losing battle. A survey compiled by Merck Serono found that 75% of oncologists believe there are barriers preventing the use of personalised medicines within the UK's National Health Service, with the cost of in vitro diagnostics pinpointed as the main issue.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT098877

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel